PMC:7195088 / 26137-29724
Annnotations
LitCovid-PD-FMA-UBERON
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T26 | 2932-2938 | Body_part | denotes | plasma | http://purl.org/sig/ont/fma/fma62970 |
T27 | 3198-3201 | Body_part | denotes | IgM | http://purl.org/sig/ont/fma/fma62873 |
T28 | 3260-3263 | Body_part | denotes | IgG | http://purl.org/sig/ont/fma/fma62872 |
LitCovid-PD-UBERON
Id | Subject | Object | Predicate | Lexical cue | uberon_id |
---|---|---|---|---|---|
T20 | 2389-2394 | Body_part | denotes | scale | http://purl.obolibrary.org/obo/UBERON_0002542 |
T21 | 2876-2881 | Body_part | denotes | Scale | http://purl.obolibrary.org/obo/UBERON_0002542 |
T22 | 3571-3576 | Body_part | denotes | scale | http://purl.obolibrary.org/obo/UBERON_0002542 |
LitCovid-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T129 | 408-416 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T130 | 527-535 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T131 | 637-645 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T132 | 794-802 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T133 | 1072-1080 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T134 | 1150-1158 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T135 | 1270-1278 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T136 | 1426-1434 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T137 | 1475-1483 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T138 | 1665-1673 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T139 | 1789-1797 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T140 | 1923-1931 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T141 | 2047-2055 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T142 | 2058-2067 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
T143 | 2154-2162 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T144 | 2306-2314 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T145 | 2512-2520 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T146 | 2754-2762 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T147 | 2850-2858 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T148 | 3052-3060 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T149 | 3202-3210 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T150 | 3452-3460 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
LitCovid-PD-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T136 | 127-128 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T137 | 201-206 | http://purl.obolibrary.org/obo/CLO_0007225 | denotes | label |
T138 | 281-282 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T139 | 343-344 | http://purl.obolibrary.org/obo/CLO_0001021 | denotes | b |
T140 | 809-814 | http://purl.obolibrary.org/obo/CLO_0007225 | denotes | label |
T141 | 874-875 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T142 | 921-922 | http://purl.obolibrary.org/obo/CLO_0001021 | denotes | b |
T143 | 1087-1092 | http://purl.obolibrary.org/obo/CLO_0007225 | denotes | label |
T144 | 1183-1188 | http://purl.obolibrary.org/obo/NCBITaxon_10239 | denotes | virus |
T145 | 1405-1406 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T146 | 1446-1448 | http://purl.obolibrary.org/obo/CLO_0050509 | denotes | 27 |
T147 | 1458-1459 | http://purl.obolibrary.org/obo/CLO_0001021 | denotes | b |
T148 | 1495-1497 | http://purl.obolibrary.org/obo/CLO_0050509 | denotes | 27 |
T149 | 1540-1542 | http://purl.obolibrary.org/obo/CLO_0050509 | denotes | 27 |
T150 | 1585-1587 | http://purl.obolibrary.org/obo/CLO_0050509 | denotes | 27 |
T151 | 2017-2018 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T152 | 2278-2279 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T153 | 2349-2350 | http://purl.obolibrary.org/obo/CLO_0001021 | denotes | b |
T154 | 2371-2374 | http://purl.obolibrary.org/obo/CLO_0001577 | denotes | a 3 |
T155 | 2527-2532 | http://purl.obolibrary.org/obo/CLO_0007225 | denotes | label |
T156 | 2932-2938 | http://purl.obolibrary.org/obo/UBERON_0001969 | denotes | plasma |
T157 | 3067-3072 | http://purl.obolibrary.org/obo/CLO_0007225 | denotes | label |
T158 | 3132-3133 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T159 | 3145-3150 | http://purl.obolibrary.org/obo/NCBITaxon_10239 | denotes | virus |
T160 | 3185-3186 | http://purl.obolibrary.org/obo/CLO_0001021 | denotes | b |
T161 | 3553-3556 | http://purl.obolibrary.org/obo/CLO_0001608 | denotes | a 7 |
LitCovid-PD-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T352 | 26-44 | Chemical | denotes | hydroxychloroquine | http://purl.obolibrary.org/obo/CHEBI_5801 |
T353 | 201-206 | Chemical | denotes | label | http://purl.obolibrary.org/obo/CHEBI_35209 |
T354 | 475-493 | Chemical | denotes | hydroxychloroquine | http://purl.obolibrary.org/obo/CHEBI_5801 |
T355 | 498-511 | Chemical | denotes | ascorbic acid | http://purl.obolibrary.org/obo/CHEBI_22652|http://purl.obolibrary.org/obo/CHEBI_29073 |
T357 | 507-511 | Chemical | denotes | acid | http://purl.obolibrary.org/obo/CHEBI_37527 |
T358 | 683-694 | Chemical | denotes | tocilizumab | http://purl.obolibrary.org/obo/CHEBI_64360 |
T359 | 700-718 | Chemical | denotes | hydroxychloroquine | http://purl.obolibrary.org/obo/CHEBI_5801 |
T360 | 724-736 | Chemical | denotes | azithromycin | http://purl.obolibrary.org/obo/CHEBI_2955 |
T361 | 741-752 | Chemical | denotes | tocilizumab | http://purl.obolibrary.org/obo/CHEBI_64360 |
T362 | 758-776 | Chemical | denotes | hydroxychloroquine | http://purl.obolibrary.org/obo/CHEBI_5801 |
T363 | 809-814 | Chemical | denotes | label | http://purl.obolibrary.org/obo/CHEBI_35209 |
T364 | 1020-1038 | Chemical | denotes | hydroxychloroquine | http://purl.obolibrary.org/obo/CHEBI_5801 |
T365 | 1087-1092 | Chemical | denotes | label | http://purl.obolibrary.org/obo/CHEBI_35209 |
T366 | 1222-1240 | Chemical | denotes | hydroxychloroquine | http://purl.obolibrary.org/obo/CHEBI_5801 |
T367 | 1321-1331 | Chemical | denotes | inhibitors | http://purl.obolibrary.org/obo/CHEBI_35222 |
T368 | 1612-1630 | Chemical | denotes | hydroxychloroquine | http://purl.obolibrary.org/obo/CHEBI_5801 |
T369 | 1858-1877 | Chemical | denotes | lopinavir/ritonavir | http://purl.obolibrary.org/obo/CHEBI_145924 |
T370 | 1858-1867 | Chemical | denotes | lopinavir | http://purl.obolibrary.org/obo/CHEBI_31781 |
T371 | 1868-1877 | Chemical | denotes | ritonavir | http://purl.obolibrary.org/obo/CHEBI_45409 |
T372 | 2108-2126 | Chemical | denotes | hydroxychloroquine | http://purl.obolibrary.org/obo/CHEBI_5801 |
T373 | 2422-2432 | Chemical | denotes | remdesivir | http://purl.obolibrary.org/obo/CHEBI_145994 |
T374 | 2437-2455 | Chemical | denotes | hydroxychloroquine | http://purl.obolibrary.org/obo/CHEBI_5801 |
T375 | 2460-2470 | Chemical | denotes | remdesivir | http://purl.obolibrary.org/obo/CHEBI_145994 |
T376 | 2476-2494 | Chemical | denotes | hydroxychloroquine | http://purl.obolibrary.org/obo/CHEBI_5801 |
T377 | 2527-2532 | Chemical | denotes | label | http://purl.obolibrary.org/obo/CHEBI_35209 |
T378 | 2668-2687 | Chemical | denotes | lopinavir/ritonavir | http://purl.obolibrary.org/obo/CHEBI_145924 |
T379 | 2668-2677 | Chemical | denotes | lopinavir | http://purl.obolibrary.org/obo/CHEBI_31781 |
T380 | 2678-2687 | Chemical | denotes | ritonavir | http://purl.obolibrary.org/obo/CHEBI_45409 |
T381 | 2692-2710 | Chemical | denotes | hydroxychloroquine | http://purl.obolibrary.org/obo/CHEBI_5801 |
T382 | 2715-2723 | Chemical | denotes | losartan | http://purl.obolibrary.org/obo/CHEBI_6541 |
T383 | 2944-2962 | Chemical | denotes | hydroxychloroquine | http://purl.obolibrary.org/obo/CHEBI_5801 |
T384 | 2968-2980 | Chemical | denotes | azithromycin | http://purl.obolibrary.org/obo/CHEBI_2955 |
T385 | 2985-3003 | Chemical | denotes | hydroxychloroquine | http://purl.obolibrary.org/obo/CHEBI_5801 |
T386 | 3009-3021 | Chemical | denotes | azithromycin | http://purl.obolibrary.org/obo/CHEBI_2955 |
T387 | 3067-3072 | Chemical | denotes | label | http://purl.obolibrary.org/obo/CHEBI_35209 |
T388 | 3308-3327 | Chemical | denotes | lopinavir/ritonavir | http://purl.obolibrary.org/obo/CHEBI_145924 |
T389 | 3308-3317 | Chemical | denotes | lopinavir | http://purl.obolibrary.org/obo/CHEBI_31781 |
T390 | 3318-3327 | Chemical | denotes | ritonavir | http://purl.obolibrary.org/obo/CHEBI_45409 |
T391 | 3332-3350 | Chemical | denotes | hydroxychloroquine | http://purl.obolibrary.org/obo/CHEBI_5801 |
T392 | 3355-3374 | Chemical | denotes | lopinavir/ritonavir | http://purl.obolibrary.org/obo/CHEBI_145924 |
T393 | 3355-3364 | Chemical | denotes | lopinavir | http://purl.obolibrary.org/obo/CHEBI_31781 |
T394 | 3365-3374 | Chemical | denotes | ritonavir | http://purl.obolibrary.org/obo/CHEBI_45409 |
T395 | 3380-3390 | Chemical | denotes | interferon | http://purl.obolibrary.org/obo/CHEBI_52999 |
T396 | 3391-3395 | Chemical | denotes | beta | http://purl.obolibrary.org/obo/CHEBI_10545 |
T397 | 3403-3413 | Chemical | denotes | remdesivir | http://purl.obolibrary.org/obo/CHEBI_145994 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T194 | 136-260 | Sentence | denotes | Double-blind RCT for outpatients and healthcare workers and open-label RCT for inpatients (NCT04329923, not yet recruiting). |
T195 | 261-458 | Sentence | denotes | Primary endpoints: (a) release from quarantine (outpatients, follow-up 14 days); (b) discharge (inpatients, follow-up 14 days); (c) development of COVID-19 (healthcare workers, follow-up 2 months). |
T196 | 459-545 | Sentence | denotes | • Comparison of hydroxychloroquine vs. ascorbic acid in contacts of COVID-19 patients. |
T197 | 546-597 | Sentence | denotes | Double-blind RCT (NCT04328961, not yet recruiting). |
T198 | 598-666 | Sentence | denotes | Primary endpoint: laboratory-confirmed COVID-19 (follow-up 14 days). |
T199 | 667-803 | Sentence | denotes | • Comparison of tocilizumab plus hydroxychloroquine plus azithromycin vs. tocilizumab plus hydroxychloroquine in patients with COVID-19. |
T200 | 804-853 | Sentence | denotes | Open-label RCT (NCT04332094, not yet recruiting). |
T201 | 854-1081 | Sentence | denotes | Primary endpoints: (a) in-hospital mortality (follow-up 2 weeks); (b) need for mechanical ventilation in the ICU (follow-up 2 weeks).• Comparison of ciclesonide plus hydroxychloroquine vs. ciclesonide in patients with COVID-19. |
T202 | 1082-1131 | Sentence | denotes | Open-label RCT (NCT04330586, not yet recruiting). |
T203 | 1132-1205 | Sentence | denotes | Primary endpoint: SARS-CoV-2 eradication (based on virus load) at day 14. |
T204 | 1206-1332 | Sentence | denotes | • Comparison of hydroxychloroquine vs. placebo in patients with COVID-19 and under biological treatment and/or JAK inhibitors. |
T205 | 1333-1384 | Sentence | denotes | Double-blind RCT (NCT04330495, not yet recruiting). |
T206 | 1385-1595 | Sentence | denotes | Primary endpoints: (a) incidence rate of COVID-19 (follow-up 27 weeks); (b) prevalence of COVID-19 (follow-up 27 weeks); (c) case fatality rate (follow-up 27 weeks); (d) ICU admission rate (follow-up 27 weeks). |
T207 | 1596-1704 | Sentence | denotes | • Comparison of hydroxychloroquine vs. placebo for the prevention of COVID-19 in healthcare workers at risk. |
T208 | 1705-1756 | Sentence | denotes | Double-blind RCT (NCT04328467, not yet recruiting). |
T209 | 1757-1819 | Sentence | denotes | Primary endpoint: prevalence of COVID-19 (follow-up 12 weeks). |
T210 | 1820-1932 | Sentence | denotes | • Comparison of chemoprophylaxis with lopinavir/ritonavir vs. placebo in healthcare workers exposed to COVID-19. |
T211 | 1933-1984 | Sentence | denotes | Double-blind RCT (NCT04328285, not yet recruiting). |
T212 | 1985-2002 | Sentence | denotes | Primary endpoint: |
T213 | 2003-2091 | Sentence | denotes | Occurrence of a symptomatic or asymptomatic SARS-CoV-2 infection (follow-up 2.5 months). |
T214 | 2092-2213 | Sentence | denotes | • Comparison of hydroxychloroquine vs. placebo in symptomatic COVID-19 patients or exposed healthcare workers/households. |
T215 | 2214-2257 | Sentence | denotes | Double-blind RCT (NCT04308668, recruiting). |
T216 | 2258-2405 | Sentence | denotes | Primary endpoints: (a) incidence of symptomatic COVID-19 among asymptomatic participants; (b) severity rating on a 3-point ordinal scale at day 14. |
T217 | 2406-2521 | Sentence | denotes | • Comparison of remdesivir vs. hydroxychloroquine vs. remdesivir plus hydroxychloroquine in patients with COVID-19. |
T218 | 2522-2580 | Sentence | denotes | Open-label adaptive RCT (NCT04321616, not yet recruiting). |
T219 | 2581-2651 | Sentence | denotes | Primary endpoint: all-cause in-hospital mortality (follow-up 3 weeks). |
T220 | 2652-2763 | Sentence | denotes | • Comparison of lopinavir/ritonavir vs. hydroxychloroquine vs. losartan vs. placebos in patients with COVID-19. |
T221 | 2764-2825 | Sentence | denotes | Double-blind, adaptive RCT (NCT04328012, not yet recruiting). |
T222 | 2826-2902 | Sentence | denotes | Primary endpoint: NIAID COVID-19 Ordinal Severity Scale (follow-up 60 days). |
T223 | 2903-3061 | Sentence | denotes | • Comparison of convalescent plasma plus hydroxychloroquine plus azithromycin vs. hydroxychloroquine plus azithromycin in hospitalized patients with COVID-19. |
T224 | 3062-3111 | Sentence | denotes | Open-label RCT (NCT04332835, not yet recruiting). |
T225 | 3112-3291 | Sentence | denotes | Primary endpoints: (a) change in virus load at days 0, 4, 7, 14 and 28; (b) change in IgM COVID-19 titers at days 0, 4, 7, 14 and 28; (c) change in IgG at days 0, 4, 7, 14 and 28. |
T226 | 3292-3461 | Sentence | denotes | • Comparison of lopinavir/ritonavir vs. hydroxychloroquine vs. lopinavir/ritonavir plus interferon beta-1a vs. remdesivir vs. standard of care in patients with COVID-19. |
T227 | 3462-3515 | Sentence | denotes | Double-blind, adaptive RCT (NCT04315948, recruiting). |
T228 | 3516-3587 | Sentence | denotes | Primary endpoint: severity rating on a 7-point ordinal scale at day 15. |